ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

So all-in-all, the ASCO meeting was a showcase for advances and progress. Taken together, these studies, along with many others reported at the meeting, ...

The American Society of Clinical Oncology (ASCO) has been notified of a recent safety notice for the drug Jubbonti (denosumab-bbdz) under the Food and Drug Administration’s Risk Evaluation and ...

Decentralized clinical trial elements can be safely adopted as permanent fixtures without substantial reductions in data quality or increased risk to research participants, according to a new study in ...

An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This ...

Latest data of InnoCare’s robust oncology pipelines were presented at the 2025 ASCO Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and ...

Inside ASCO 2025: Big data drops and a towering campaign By Ayla Ellison, Angus Liu, Gabrielle Masson, Zoey Becker Jun 6, 2025 10:39am The Top Line ASCO 2025 Enhertu Johnson & Johnson ...

SHANGHAI, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting successfully concluded in Chicago on June 3 (local time). Hengrui Pharma delivered a strong international presence, featuring 15 ...

Vepdegestrant, an oral oestrogen receptor (ER) degrader, improves outcomes in selected patients with ER-positive, HER2-negative advanced breast cancer. In the phase 3 VERITAC-2 trial, presented by ...

Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg/kg ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

HealthDay News — For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted ...